Healthcare providers are looking to medical devices to play a new role in hospital care, providing a whole-patient view of health through technologies that talk to each other and help clinicians make decisions about treatment.
Veniti founder, president & CEO Sean Morris is on the march, looking to take over venous disease treatment with a suit of specialized devices that he hopes will knock out their more generic forebears.
Veniti, formed in 2009, specializes in devices for the venous anatomy, an arena often covered in a larger medical device company’s vascular devices business.
Philipp Lang has ConforMIS looking to get a leg up on the knee replacement industry.
Last week, the Burlington, Mass.-based orthopedic implant maker said it raised $89 million in a Series E round from several investors, bringing the total nut raised by ConforMIS over the last 3 years to more than $140 million – a somewhat remarkable amount, given the fundraising climate over the past few years.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this Halloween, make sure you’re still in the know with MassDevice +3.
Venipuncture – drawing blood or establishing an intravenous feed – is the most common invasive medical procedure. For many patients, it’s a painful exercise in frustration when clinicians struggle to find a blood vessel, sometimes requiring multiple needle sticks.
AccuVein and CEO Ron Goldman aim to change all that with the company’s AV300 vascular illumination device. The wireless, handheld module uses a pair of lasers to paint a patient’s arm with light, making otherwise invisible or hard-to-find blood vessels apparent to the naked eye.
Neuronetics’ NeuroStar TMS therapy system
Neuronetics Inc. is paving the way for a new type of depression therapy, a non-invasive electromagnetic field treatment designed to stimulate brain cells linked to depression.
Bruce Shook, co-founder, president & CEO, talked to MassDevice about pioneering the market for the only FDA-cleared transcranial magnetic stimulation system to date, his company’s NeuroStar TMS system.
The therapy, which won the FDA nod in 2008, is a rarity in the med-tech world: A device-based approach to a psychiatric disorder.